
FLGT
NSDFulgent Genetics Inc.
Healthcare•Diagnostics & Research
Watchlists:
Last updated: Sunday 20th July 2025
17.78
-0.35 (-1.93%)
Prev Close:18.13
Open:18.26
Bid:17.78
Ask:17.94
52 Week Range
14.5725.11
Volume:287,092
Mkt Cap:550 M
38
MarketXLS Rank ®
Weak Hold
Price Target
$20.45
+15.0%
Financial Statements
FLGT - Income Statement (Annual)
Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Invalid date | |
---|---|---|---|---|---|---|---|---|---|---|
Accretion On Preferred Stock | -5 M | |||||||||
Acquired In Process Rn D Income | -5 M | |||||||||
Commission Expenses | 90 M | |||||||||
Cumulative Effect Of Accounting Change | 239000.0 | |||||||||
Depreciation And Amortization | 8 M | 8 M | 7 M | 2 M | 3 M | 2 M | -2 M | -2 M | -1 M | |
Earnings From Equity Interest | -488000.0 | -777000.0 | -935000.0 | -524000.0 | ||||||
Earnings From Equity Interest Net Of Tax | -488000.0 | -777000.0 | -935000.0 | -524000.0 | ||||||
Gain On Sale Of Business | 481000.0 | |||||||||
Gain On Sale Of Security | 131000.0 | 32000.0 | 104000.0 | 164000.0 | 163000.0 | |||||
General And Administrative Expense | 88 M | 89 M | 111 M | 51 M | 15 M | 21 M | 6 M | 5 M | 5 M | |
Gross Profit Margin (profit Margin After CGS) | 107 M | 104 M | 367 M | 777 M | 332 M | 18 M | 11 M | 10 M | 12 M | |
Impairment Of Capital Assets | 120 M | 216 M | ||||||||
Interest Expense Non Operating | -170000.0 | 488000.0 | 117000.0 | 20000.0 | ||||||
Minority Interests | 1 M | 7 M | 1 M | 1 M | 569 M | |||||
Misc Other Special Charges | 561000.0 | 320000.0 | 26 M | 257000.0 | 59000.0 | 16000.0 | ||||
Net Income (loss) | -43 M | -168 M | 143 M | 507 M | 214 M | -411000.0 | -6 M | -3 M | -5 M | |
Net Income Common Stockholders | -43 M | -168 M | 143 M | 507 M | 214 M | -411000.0 | -6 M | -3 M | -5 M | |
Net Income Continuous Operations | -44 M | -175 M | 142 M | 507 M | 214 M | -411000.0 | -6 M | -3 M | -5 M | |
Net Income Discontinuous Operations | 400000.0 | |||||||||
Net Income From Other Gains Losses | 4 M | -4 M | ||||||||
Net Non Operating Interest Income Expense | 31 M | 21 M | 5 M | 1 M | 2 M | 837000.0 | 434000.0 | |||
Operating Income | -74 M | -196 M | 179 M | 676 M | 290 M | -428000.0 | -5 M | -3 M | 918000.0 | |
Operating Income Before Depreciation (EBITDA) | -23 M | -141 M | 217 M | 687 M | 293 M | 3 M | -2 M | -903000.0 | -3 M | |
Operating Expense | 181 M | 300 M | 188 M | 101 M | 42 M | 19 M | -16 M | -14 M | -11 M | |
Other Gand A | 88 M | 89 M | 111 M | 51 M | 15 M | 21 M | 6 M | 5 M | 5 M | |
Other Impairment Of Capital Assets | 4 M | |||||||||
Other Operating Expenses | 188 M | -333000.0 | -236000.0 | 19 M | -16 M | -14 M | -11 M | |||
Other Write Off | 499000.0 | 23000.0 | 28000.0 | -6000.0 | -24000.0 | -27000.0 | ||||
Otherunder Preferred Stock Dividend | -5 M | |||||||||
Preferred Stock Dividends | -5 M | |||||||||
Realized Capital Gain | 434000.0 | |||||||||
Rent And Landing Fees | 6 M | 5 M | 5 M | |||||||
Research Expense | 49 M | 41 M | 29 M | 24 M | 12 M | 7 M | 6 M | 4 M | 4 M | |
Restructring And Mn A Income | 3 M | |||||||||
Salaries And Wages | -3 M | -2 M | -2 M | -5 M | ||||||
Selling And Marketing Expense | 36 M | 41 M | 39 M | 24 M | 105 M | 6 M | 5 M | 4 M | 2 M | |
Selling Expense | 6 M | 5 M | 4 M | 2 M | ||||||
Total Income Available For Interest Expense (EBIT) | -52 M | -174 M | 184 M | 676 M | 290 M | 409000.0 | -5 M | -3 M | -4 M | |
Total Revenues | 283 M | 289 M | 619 M | 993 M | 422 M | 33 M | 21 M | 19 M | 18 M | |
Total Expenses | 357 M | 485 M | 440 M | 317 M | 132 M | 33 M | -26 M | -22 M | -17 M | |
Total Revenue | 283 M | 289 M | 619 M | 993 M | 422 M | 33 M | 21 M | 19 M | 18 M | |
Write Off | 216 M | |||||||||
Amord | 8 M | 8 M | 7 M | 2 M | ||||||
Avgshs | 30 M | 30 M | 30 M | 29 M | 23 M | 19 M | 18 M | 18 M | 14 M | |
Avgshsdt | 30 M | 30 M | 31 M | 31 M | 24 M | 19 M | 18 M | 18 M | 108 M | |
Basiceps | -1.41 | -5.63 | 4.76 | 17.25 | 9.44 | -0.02 | -0.11 | -0.09 | 0.05 | |
Basicepscont | -1.41 | -5.63 | 4.76 | 17.25 | 9.44 | -0.02 | -0.31 | -0.14 | ||
Cor | 176 M | 185 M | 252 M | 216 M | 90 M | 14 M | -11 M | -9 M | -7 M | |
Depamor | 8 M | 8 M | 7 M | 9 M | 3 M | 2 M | -2 M | -2 M | -1 M | |
Dileps | -1.41 | -5.63 | 4.63 | 16.38 | 8.91 | -0.02 | -0.11 | -0.09 | 0.05 | |
Dilepscont | -1.41 | -5.63 | 4.63 | 16.38 | 8.91 | -0.02 | -0.31 | -0.14 | ||
Intinc | 31 M | 22 M | 5 M | 1 M | 2 M | 837000.0 | 434000.0 | |||
Netincdisc | -43 M | -168 M | 143 M | 507 M | 214 M | -411000.0 | -6 M | -3 M | -5 M | |
Othincexp | -561000.0 | -320000.0 | -3 M | -28 M | 488000.0 | 777000.0 | 935000.0 | 524000.0 | 5 M | |
Pretaxinc | -52 M | -174 M | 184 M | 677 M | 292 M | 409000.0 | -5 M | -3 M | -4 M | |
Resdev | 49 M | 41 M | 29 M | 24 M | 12 M | 7 M | 6 M | 4 M | 4 M | |
Restruct | 3 M | |||||||||
Sga | 124 M | 130 M | 150 M | 75 M | 120 M | 26 M | 10 M | 9 M | 7 M | |
Shsout | 31 M | 30 M | 30 M | 30 M | 29 M | 22 M | 18 M | 18 M | 18 M | |
Specincchg | -120 M | -3 M | -216 M | |||||||
Taxprov | -8 M | 1 M | 42 M | 175 M | 73 M | 43000.0 | 36000.0 | -1 M | 920000.0 |